111in-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours

British Journal of Surgery

Volumn 90, Issue 5, 2003, Pages 549-554

  Hashemi, S H ^a   Benjegard S A ^a   Ahlman, H ^a   Wangberg B ^a   Forssell Aronsson, E ^a   Billig, H ^a   Nilsson, O ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; CHELATING AGENT; DIAGNOSTIC AGENT; HORMONE; INDIUM; OCTREOTIDE; PENTETIC ACID;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CARCINOID; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE TUMOR; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ASSAY; RIBONUCLEASE PROTECTION ASSAY; SCINTISCANNING; THYROID MEDULLARY CARCINOMA; TUMOR BIOPSY; BIOPSY; BREAST TUMOR; METABOLISM; MIDDLE AGED;

ADULT; AGED; BIOPSY; BREAST NEOPLASMS; CHELATING AGENTS; FEMALE; HORMONES; HUMANS; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PENTETIC ACID; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER;

EID: 0038292078     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4069     Document Type: Article

References (21)

1. Reubi JC, Krenning E, Lamberts SW, Kvols L. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 1990; 37: 1073-1077.
2. Nilsson O, Kölby L, Wängberg B, Wigander A, Billig H, William-Olsson L et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998; 77: 632-637.
3. Reubi JC, Hacki WH, Lamberts SW. Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 1987; 65: 1127-1134.
4. Raulf F, Perez J, Hoyer D, Bruns C. Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. Digestion 1994; 55: 46-53.
5. Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D et al. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci 1994; 733: 138-146.
6. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994; 135: 2814-2817.
7. Shulkes A. Somatostatin: physiology and clinical applications. Baillieres Clin Endocrinol Metab 1994; 8: 215-236.
8. Ahlman H, Wängberg B, Tisell LE, Nilsson O, Fjälling M, Forssell-Aronsson E. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg 1994; 81: 1144-1149.
9. Krenning EP, Kooij PP, Pauwels S, Breeman WA, Postema PT, De Herder WW et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996; 57(Suppl 1): 57-61.
10. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998; 351:417-418 (Letter).
11. Andersson P, Forssell-Aronsson E, Johanson V, Wängberg B, Nilsson O, Fjälling M et al. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phel-octreotide. J Nucl Med 1996; 37: 2002-2006.
12. John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherubl H et al. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 1996; 38: 33-39.
13. Forssell-Aronsson E, Fjälling M, Nilsson O, Tisell LE, Wängberg B, Ahlman H. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J Nucl Med 1995; 36: 7-12.
14. Wängberg B, Forssell-Aronsson E, Tisell LE, Nilsson O, Fjälling M, Ahlman H. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide. Br J Cancer 1996; 73: 770-775.
15. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 2000; 41: 636-642.
16. Skånberg J, Ahlman H, Benjegard SA, Fjälling M, Forssell-Aronsson EB, Hashemi SH et al. Indium-111-octreotide scintigraphy, intraoperative gamma-detector localisation and somatostatin receptor expression in primary human breast cancer. Breast Cancer Res Treat 2002; 74: 101-111.
17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
18. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994; 93: 1321-1325.
19. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996; 37: 912-916.
20. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
21. Tisell LE, Ahlman H, Wängberg B, Hansson G, Mölne J, Nilsson O et al. Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg 1997; 84: 543-547.